UNSPSC 51112401: Amifostine monohydrate

This classification denotes a cytoprotective agent with the molecular formula C5H15N2O3PS.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L693H6MM64, chemically known as ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester), monohydrate, but more generally known as amifostine monohydrate, which bears US NIH Compound Identifier 83996. European Medicines Agency schedules amifostine monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12846MIG.

Most nations, for tariff and trade purposes, schedule amifostine monohydrate under HS 29309085. SMILES: C(CN)CNCCSP(=O)(O)O.O.

UNSPSC 51112401 Amifostine monohydrate is a Commodity code representing a specific pharmaceutical product — amifostine monohydrate, a cytoprotective agent used in clinical settings — but state and local governments show minimal direct procurement activity under this code. The single recent opportunity on record is a Request for Information (RFI) from the Texas Health and Human Services Commission issued April 3, 2026, but the RFI addresses pharmacy benefit program infrastructure and direct-to-manufacturer prescription fulfillment capabilities rather than procurement of amifostine monohydrate itself. The RFI solicits vendor information about establishing direct contracting relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management, with emphasis on vendors' experience in direct contracting for self-insured employers and health plans, flexibility to negotiate based on net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements.

The code shows no identifiable recent activity in other state or local jurisdictions. The Texas RFI represents a preliminary market-intelligence gathering phase designed to inform the HHS Commission's future procurement strategy before issuing a formal Request for Proposal; no award value, budget allocation, or timeline for formal solicitation is specified. Because the single recent opportunity tagged to this code addresses program structure and vendor capabilities rather than direct purchase of the pharmaceutical commodity itself, the code does not present a clear signal of active state and local buying demand for amifostine monohydrate at this time.